_256_384.jpg)
The Indian companies that have been granted licences are Cipla, Sun Pharma, Laurus Labs, Divis Labs, Glenmark, Cadila, Torrent, Emcure, McLeods, SMS Pharmaceuticals, Strides, Biocon, Aurobindo Pharma, Hetero, Granules, Amneal, MSN, Arene Life Sciences and Viatris
EUROAPI listing on Euronext Paris will occur in H1 2022, despite volatile market conditions
Jointly fund and develop up to three antibody-drug conjugate programs for the treatment of cancer
Selvax's goal is to develop safe, effective and immunological-based treatments for a range of hard-to-treat solid tumours
This collaboration has resulted in several high-impact scientific publications describing breakthrough inventions, including the SOMA robotic pill, which has subsequently been licensed exclusively to Novo Nordisk for clinical development
Alvotech expects AVT02 (adalimumab) will be marketed in the U.S., subject to regulatory approval, on July 1, 2023
Agreement builds on previous Novartis success using emerging technologies to develop first-in-class gene therapies for neurological disorders
Taisho Pharmaceutical will bring its experience and expertise in the research and development of therapeutic products to the collaboration.
Around 85% of ALS patients suffer from a progressive loss of bulbar functionality
Launched in 2020, C-TAP aims to facilitate timely, equitable and affordable access to Covid-19 health products by boosting their production and supply through open, non-exclusive licensing agreements
Subscribe To Our Newsletter & Stay Updated
